Cargando…

Sustained high trough factor IX activity levels with continued use of rIX‐FP in adult and paediatric patients with haemophilia B

Detalles Bibliográficos
Autores principales:	Gill, Joan C., Roberts, John, Li, Yanyan, Castaman, Giancarlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Online Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7065198/ https://www.ncbi.nlm.nih.gov/pubmed/30866086 http://dx.doi.org/10.1111/hae.13735

Ejemplares similares

Health‐related quality of life in paediatric haemophilia B patients treated with rIX‐FP
por: von Mackensen, Sylvia, et al.
Publicado: (2018)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis
por: Hermans, Cedric, et al.
Publicado: (2020)

High adherence to prophylaxis regimens in haemophilia B patients receiving rIX‐FP: Evidence from clinical trials and real‐world practice
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Long-Acting Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Children: Results of a Phase 3 Trial
por: Kenet, Gili, et al.
Publicado: (2016)

Long‐term safety and efficacy of rIX‐FP prophylaxis with extended dosing intervals up to 21 days in adults/adolescents with hemophilia B
por: Mancuso, Maria Elisa, et al.
Publicado: (2020)

Efficacy of rFIXFc versus rIX-FP for the Treatment of Patients with Hemophilia B: Matching-Adjusted Indirect Comparison of B-LONG and PROLONG-9FP Trials
por: Astermark, Jan, et al.
Publicado: (2021)

Excellent hemostatic control during cardiac surgery in a patient with hemophilia B treated with albutrepenonacog alfa (rIX‐FP): A case report
por: López‐Jaime, Francisco José, et al.
Publicado: (2023)

Real‐world experience of rIX‐FP prophylaxis at dosing intervals of up to 14 days in a pediatric patient with hemophilia B during the COVID‐19 pandemic
por: Díaz‐Jordán, Bolívar Luis, et al.
Publicado: (2023)

Treatment and Prevention of Bleeds in Haemophilia Patients with Inhibitors to Factor VIII/IX
por: Rocino, Angiola, et al.
Publicado: (2017)

Population Pharmacokinetic Modelling of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Patients with Haemophilia B
por: Diao, Lei, et al.
Publicado: (2014)

Budget impact analysis of extended half-life recombinant factor IX (rFIXFc) in the treatment of haemophilia B
por: Aiello, Andrea, et al.
Publicado: (2020)

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
por: Fukutake, Katsuyuki, et al.
Publicado: (2019)

DeltaPhage—a novel helper phage for high-valence pIX phagemid display
por: Nilssen, Nicolay R., et al.
Publicado: (2012)

Genes IX /
por: Lewin, Benjamin
Publicado: (2008)

Genes IX /
por: Lewin, Benjamin
Publicado: (2008)

Hæmatology—IX
Publicado: (1910)

IX Year
Publicado: (1873)

Situations, IX : Mélanges
por: Sartre, Jean-Paul, 1905-1980
Publicado: (1972)

Updates in clinical trial data of extended half-life recombinant factor IX products for the treatment of haemophilia B
por: Mahlangu, Johnny N.
Publicado: (2018)

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update
por: Aiello, Andrea, et al.
Publicado: (2022)

Optimal trough levels in haemophilia B: Raising expectations
por: Walsh, Christopher, et al.
Publicado: (2020)

Complex Networks IX
por: Cornelius, Sean, et al.
Publicado: (2018)

Gaseous dielectrics IX
por: Christophorou, Loucas G, et al.
Publicado: (2001)

Acridine form IX
por: Stephens, Peter W., et al.
Publicado: (2019)

Chapter IX. Of Carbuncles
Publicado: (1894)

Abstracts for ISVEE IX
Publicado: (2007)

Enhanced Factor IX Activity following Administration of AAV5-R338L “Padua” Factor IX versus AAV5 WT Human Factor IX in NHPs
por: Spronck, Elisabeth A., et al.
Publicado: (2019)

Chapter IX: Two Theoretical Talks: IX.1 Compositeness: the supercollider frontier
por: Peccei, Roberto D
Publicado: (1984)

Immune responses to human factor IX in haemophilia B mice of different genetic backgrounds are distinct and modified by TLR4
por: Sack, B K, et al.
Publicado: (2015)

Expression and prognostic value of carbonic anhydrase IX (CA-IX) in bladder urothelial carcinoma
por: Xiang, An-Ping, et al.
Publicado: (2022)

F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes
por: Branchini, Alessio, et al.
Publicado: (2021)

Séminaire de probabilités IX
por: Meyer, P A
Publicado: (1975)

Light Scattering in Solid IX
por: Cardona, Manuel, et al.
Publicado: (2007)

Geometry and topology of submanifolds Ix
por: Verstraelen, L, et al.
Publicado: (1999)

Probability Measures on Groups IX
por: Heyer, Herbert
Publicado: (1989)

Transactions on rough sets IX
por: Peters, James F, et al.
Publicado: (2008)

The Cost of Provisions in Institutions.—IX
Publicado: (1904)

Hæmatological Technique: Part IX
por: Napier, L. Everard, et al.
Publicado: (1941)

Diet in Disease: IX. Digestion
por: Hart, Ernest
Publicado: (1892)

Cannot write session to /tmp/vufind_sessions/sess_uc1dtd5el5srgoa1l8b9s37hfv